11.00\u201311.45 Registration and lunch<\/strong><\/p>\n\n\n\n 11.45\u201312.15 Opening of the 20th<\/sup> Annual FinPharmaNet Meeting<\/strong><\/strong> 12.15\u201313.15\u00a0\u00a0\u00a0 Session I: Drug Discovery and Molecular Mechanisms<\/strong><\/strong> 13.15\u201313.30 Break<\/strong><\/p>\n\n\n\n 13.30\u201314.30\u00a0\u00a0\u00a0 Session I continues<\/strong><\/strong><\/strong> 14.30\u201314.45 Break<\/strong><\/p>\n\n\n\n 14.45\u201316.15\u00a0\u00a0\u00a0 Session II: Innovative Formulation and Drug Delivery Technologies<\/strong><\/strong> 16.15\u201316.45 Coffee break<\/strong><\/p>\n\n\n\n 16.45\u201318.00 Session II continues<\/strong><\/strong> 18.00\u201318.30 Break<\/strong><\/p>\n\n\n\n 18.30\u201320.00 Dinner<\/strong><\/p>\n\n\n\n 20.00\u201323.00 Social program<\/strong> 9.00\u201310.30\u00a0\u00a0\u00a0\u00a0\u00a0 Session III: Clinical Applications and Personalized Therapies<\/strong><\/strong> 10.30\u201310.45 Break<\/strong><\/p>\n\n\n\n 10.45\u201311.45\u00a0\u00a0\u00a0 Session III continues<\/strong><\/strong> 11.45\u201312.45 Lunch + FinPharmaNet representatives meeting<\/strong><\/p>\n\n\n\n 12.45\u201314.10 \u00a0\u00a0 Session IV: Optimizing Medicine Use and Future Directions<\/strong> 14.10\u201314.30 Group photo + break<\/strong><\/p>\n\n\n\n 14.30\u201315.15 Session IV continues<\/strong><\/strong> 15.15\u201315.45 Awards and closing of the meeting<\/strong><\/strong><\/p>\n\n\n\n 15.45 Coffee and departure<\/strong><\/p>\n\n\n\n \ud83e\udde1 Session I: <\/strong>Drug Discovery and Molecular Mechanisms (orange)<\/em> Thursday 20 August 11.00\u201311.45 Registration and lunch 11.45\u201312.15 Opening of the 20th Annual FinPharmaNet Meeting11.45\u201311.50 Opening remarks, Prof. Anu Kauppinen, UEF11.50\u201312.15 A historical overview of FinPharmaNet, Prof. Paavo Honkakoski, UEF 12.15\u201313.15\u00a0\u00a0\u00a0 Session I: Drug Discovery and Molecular MechanismsChair: Postdoctoral Researcher Maria Hytti, UEF12.15\u201312.45 \u00a0\u00a0 Keynote: Director for Target Science Julia Lindqvist, Finnish Drug […]<\/p>\n","protected":false},"author":867,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-92","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\n
11.45\u201311.50<\/strong> Opening remarks, Prof. Anu Kauppinen<\/strong>, UEF
11.50\u201312.15<\/strong> A historical overview of FinPharmaNet, Prof. Paavo Honkakoski<\/strong>, UEF <\/p>\n\n\n\n
Chair: Postdoctoral Researcher Maria Hytti, UEF<\/em>
12.15\u201312.45<\/strong> \u00a0\u00a0 Keynote: Director for Target Science Julia Lindqvist<\/strong>, Finnish Drug Discovery Center
Selecting the Right Target for the Right Patient: Foundations for Successful Drug Discovery
12.45\u201313.00<\/strong> \u00a0\u00a0 Academy Research Fellow Tatu Pantsar<\/strong>, UEF
Small GTPases: Challenging But Not Impossible Drug Targets
13.00\u201313.15<\/strong> \u00a0\u00a0 Associate Prof. Kristiina Huttunen<\/strong>, UEF
From Yoda1 to Jedi: Translating Piezo1 Agonists from Pharmacokinetics to Rational Ligand Optimization<\/p>\n\n\n\n
13.30\u201313.40<\/strong> \u00a0\u00a0 Madushani Bandara<\/strong>, UEF
Development of stereoselective synthesis of L-amino acid-based boron delivery agents for glioma-targeted boron neutron capture therapy (BNCT)
13.40\u201313.50<\/strong> \u00a0\u00a0 Aino Majanen<\/strong>, UH
pH-Dependent phase behavior of ibuprofen-copovidone based amorphous solid dispersions using in situ<\/em> stimulated raman scattering (SRS) microscopy
13.50\u201314.00<\/strong> \u00a0\u00a0 Shujun Liang<\/strong>, \u00c5A
Granular hydrogel of photocurable cellulose nanofibers in service of 3D culture
14.00\u201314.10<\/strong> \u00a0\u00a0 Pekka Vanhanen<\/strong>, UEF
Effective process for screening melanin binding affinity of small molecule drugs and new drug candidates
14.10\u201314.20<\/strong> \u00a0\u00a0 Julius Viita<\/strong>, UEF
<\/strong>Novel melanin-binding carbonic anhydrase inhibitors for the treatment of glaucoma
14.20\u201314.30<\/strong> \u00a0\u00a0 Karla Saukkonen<\/strong>, UTU, \u00c5A
<\/strong>Development of an enzyme inhibition assay to evaluate drug-induced 7-dehydrocholesterol reductase (DHCR7) inhibition<\/p>\n\n\n\n
Chair: Prof. Heidi Kidron, UH, UEF<\/em>
14.45\u201315.15<\/strong> \u00a0\u00a0 Keynote: Prof. Hongbo Zhang<\/strong>, \u00c5A
Innovative Drug Delivery Technologies
15.15\u201315.30<\/strong> \u00a0\u00a0 Prof. Ossi Korhonen<\/strong>, UEF
Fixed-dose triple combination dispersible tablets for paediatric HIV \u2014 continuous direct compression vs. batch manufacturing
15.30\u201315.45<\/strong> \u00a0\u00a0 Head of Research Xiaoju Wang<\/strong>, \u00c5A
Sustainable biomass-derived lignin nanomaterials for antimicrobial applications
15.45\u201315.55<\/strong> \u00a0\u00a0 Rabia Gulshan<\/strong>, \u00c5A
<\/strong>Nanomaterial- and technology-driven approaches for combating antimicrobial resistance
15.55\u201316.05<\/strong> \u00a0\u00a0 Sachin Gautam<\/strong>, UH
<\/strong>Poly(jasmine lactone)-based micellar nanocarriers for improving tetracycline activity against resistant\u00a0Escherichia coli
<\/em>16.05\u201316.15<\/strong> \u00a0\u00a0 Roya Khoshtinatnikkhoy<\/strong>, UH
<\/strong>Antibiotic-coated urinary catheters for prevention of catheter-associated urinary tract infections: Comparing dipping and impregnation coating strategies<\/p>\n\n\n\n
16.45\u201316.55<\/strong> Oliver Koivisto<\/strong>, \u00c5A
<\/strong>Metal-organic framework nanoparticles as delivery vehicles for biological cargoes: From mitochondria to CRISPR\/Cas9 plasmids
16.55\u201317.05<\/strong> Zonghong Lu<\/strong>, \u00c5A
<\/strong>Lignin nanoparticles as sustainable platforms for drug delivery applications
17.05\u201317.15<\/strong> Mengxue Lu<\/strong>, UH
<\/strong>Modulating the nano-bio interface of lignin nanoparticles through chitosan coating: Effects on cellular uptake, immunostimulation, and colloidal stability in biological media
17.15\u201317.25<\/strong> Mahdieh Mozaffari Majd<\/strong>, \u00c5A
<\/strong>Influence of polymer backbone functionality and formulation method on solubilization and cellular uptake of nanoemulsions
17.25\u201317.30<\/strong> Short break
17.30\u201317.40<\/strong> Deependra Yadav<\/strong>, \u00c5A
<\/strong>NAP4DIVE: Non-animal platform for nanoparticle-based delivery across the blood-brain barrier interface with vehicle evolution
17.40\u201317.50<\/strong> Erika Pennanen<\/strong>, UEF
<\/strong>Lipidomic and metabolic characterization of ocular retinoblastoma model and investigation of tumor targeting properties of PL3 peptide using LC-MS and MALDI-MSI
17.50\u201318.00<\/strong> Ziyan Wang<\/strong>, UH
Engineering Liquid\u2013Liquid Phase Separation nano condensates for Intracellular mRNA Delivery<\/p>\n\n\n\n
Stand-up comedy performance by Fathi Ahmed<\/strong>, followed by an evening with DJ Ismo<\/strong>.
Karaoke bar Club R will be open until 01.00.
<\/p>\n\n\n\nFriday 21 August<\/h4>\n\n\n\n
Chair: Academy research fellow Tatu Lajunen, UEF<\/em>
9.00\u20139.30<\/strong> \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Keynote: Prof. Mikko Niemi<\/strong>, UH
Implementing Personalized Therapies in Healthcare: Pharmacogenomics in Practice
9.30\u20139.45<\/strong> \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Postdoctoral researcher Maha Naser<\/strong>, UH
From Dairy DRAIN TO DRUG DELIVERY: Side-Stream Lactose in Semi-Solid Extrusion 3D Printing of Orodispersible Films and Multilayer Tablets
9.45\u201310.00<\/strong> \u00a0\u00a0\u00a0\u00a0 Senior Researcher Miia Tiihonen<\/strong>, UEF
Prediction and prevention of drug adverse effects: focus on anticoagulation therapy
10.00\u201310.10<\/strong> \u00a0\u00a0 Mahsa Bahman<\/strong>, \u00c5A
Semi-solid extruded tablets for personalized pediatric use: Development, quality control and in-vitro assessment of enteral tube administration
10.10\u201310.20<\/strong>\u00a0\u00a0\u00a0 David Ekwe<\/strong>, UTU
6-[18<\/sup>F]Fluoronicotinic Acid PET Visualizes Intracranial Human Glioblastoma Xenografts that are [18<\/sup>F]FET PET Negative
10.20\u201310.30<\/strong>\u00a0\u00a0\u00a0 Greta V\u00e4lij\u00e4rvi<\/strong>, UEF
Accumulation of fluorescent polystyrene particles in perfused human placenta<\/p>\n\n\n\n
10.45\u201310.55<\/strong> \u00a0\u00a0 Maritta Keurulainen<\/strong>, UH
Broccoli extract as a potential virulence inhibitor in uropathogenic Escherichia coli
<\/em>10.55\u201311.05<\/strong> \u00a0\u00a0 Marina Castro Guerrero<\/strong>, UH
Comparative evaluation of cardiomyocyte spheroid formation and maturation under microfluidic and static 3d culture conditions
11.05\u201311.15<\/strong> \u00a0\u00a0 Khalfa Benadouda<\/strong>, UH
Synthetic HDL-based therapy for selective modulation of cholesterol efflux in atheroma macrophages
11.15\u201311.25<\/strong> \u00a0\u00a0 Hamed Maljaei<\/strong>, UEF
Organic Anion Transporting Polypeptide (OATP) -utilizing prodrugs to improve intra-brain drug delivery for neuroprotective\u00a0agent
11.25\u201311.35<\/strong> \u00a0\u00a0 Jonne Kunnas<\/strong>, \u00c5A
Biodistribution of [68Ga]Ga-labeled nanoerythrosomes
11.35\u201311.45<\/strong> \u00a0\u00a0 Emel Bakay<\/strong>, \u00c5A
Proof-of-concept study of brain metastasis PET imaging with 6-[18<\/sup>F]fluoronicotinic acid<\/p>\n\n\n\n
<\/strong>Chair: Prof. Katri H\u00e4meen-Anttila<\/em>
12.45\u201312.50<\/strong> \u00a0\u00a0 Opening the session, Prof. Katri H\u00e4meen-Anttila<\/strong>, chair
12.50\u201313.10<\/strong> \u00a0\u00a0 Keynote: Prof. Pauline Norris<\/strong>, University of Otago, New Zealand
Optimizing access to medicines
13.10\u201313.30<\/strong> \u00a0\u00a0 Assistant Prof. Katri Aaltonen<\/strong>, UH
Optimizing medicine use on a population level
13.30\u201313.50<\/strong> \u00a0\u00a0 Prof. Katri H\u00e4meen-Anttila<\/strong>, UEF
Future role of community pharmacies in optimizing medication use
13.50\u201314.10<\/strong> \u00a0\u00a0 Associate Prof. Anna-Riia Holmstr\u00f6m<\/strong>, UH
Optimizing medication use in high-risk patients and care environments<\/p>\n\n\n\n
14.30\u201314.40<\/strong> Anni Kokolahti<\/strong>, UEF
Sensitivity of register-based quality indicators to changes in indicator definition: Lipid-lowering medication use in people with type 2 diabetes
14.40\u201314.50<\/strong> Marianne Kouhia<\/strong>, UEF
Counselling roles regarding insulin treatment and automatic substitution of insulins: The perspectives of patients and healthcare professionals
14.50\u201315.00<\/strong> Leena Reinikainen<\/strong>, UEF, FIMEA
Accessibility of expensive medicines: a national register study of retail distribution in Finland in the 2000s
15.00\u201315.10<\/strong> Agnese R\u00f6nng\u00e5rd-Jalkanen<\/strong>, UEF
<\/strong>Experienced problems in pharmacotherapy monitoring and factors associated with them: A nationwide survey of medicine users
15.10\u201315.15<\/strong> End of the session<\/p>\n\n\n\n
\ud83d\udc9bSession II: <\/strong>Innovative Formulation and Drug Delivery Technologies (yellow)<\/em>
\ud83d\udc9aSession III: <\/strong>Clinical Applications and Personalized Therapies (green)<\/em>
\ud83d\udc9cSession IV: <\/strong>Optimizing Medicine Use and Future Directions (purple)<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"